[go: up one dir, main page]

WO2010011117A3 - Ndga-containing composition for the suppression of transglutaminase - Google Patents

Ndga-containing composition for the suppression of transglutaminase Download PDF

Info

Publication number
WO2010011117A3
WO2010011117A3 PCT/KR2009/004175 KR2009004175W WO2010011117A3 WO 2010011117 A3 WO2010011117 A3 WO 2010011117A3 KR 2009004175 W KR2009004175 W KR 2009004175W WO 2010011117 A3 WO2010011117 A3 WO 2010011117A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
transglutaminase
ndga
present
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/004175
Other languages
French (fr)
Korean (ko)
Other versions
WO2010011117A2 (en
Inventor
김수열
이창훈
정경채
이병일
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
National Cancer Center Korea
Original Assignee
National Cancer Center Japan
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, National Cancer Center Korea filed Critical National Cancer Center Japan
Publication of WO2010011117A2 publication Critical patent/WO2010011117A2/en
Publication of WO2010011117A3 publication Critical patent/WO2010011117A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel use of nordihydroguaiaretic acid (NDGA) for suppressing transglutaminase activity. More specifically, the present invention relates to a pharmaceutical composition which contains NDGA as an active ingredient and which is used for the prevention or treatment of neurological diseases, inflammatory diseases and cancerous diseases which are medical conditions induced by increased transglutaminase activity. Further, the present invention relates to a method for preventing or treating neurological diseases, inflammatory diseases and cancerous diseases, which are induced by increased transglutaminase activity, by the administration of the pharmaceutical composition. The novel method of the present invention for suppressing transglutaminase by using NDGA is advantageous in that it can be applied safely and without side effects in subjects having diseases involving the abnormal expression of transglutaminase, and can effectively treat or prevent such diseases.
PCT/KR2009/004175 2008-07-25 2009-07-27 Ndga-containing composition for the suppression of transglutaminase Ceased WO2010011117A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080072912 2008-07-25
KR10-2008-0072912 2008-07-25

Publications (2)

Publication Number Publication Date
WO2010011117A2 WO2010011117A2 (en) 2010-01-28
WO2010011117A3 true WO2010011117A3 (en) 2010-03-25

Family

ID=41570759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004175 Ceased WO2010011117A2 (en) 2008-07-25 2009-07-27 Ndga-containing composition for the suppression of transglutaminase

Country Status (2)

Country Link
KR (1) KR20100011963A (en)
WO (1) WO2010011117A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107449848A (en) * 2017-09-22 2017-12-08 完美（中国）有限公司 A method for identifying Laria extract in cosmetic raw materials

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
WO2008042921A2 (en) * 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
WO2008042921A2 (en) * 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use

Also Published As

Publication number Publication date
WO2010011117A2 (en) 2010-01-28
KR20100011963A (en) 2010-02-03

Similar Documents

Publication Publication Date Title
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
WO2010032140A3 (en) Pharmaceutical compositions and related methods of delivery
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP4140487A8 (en) Combination therapy for treating cancer
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2010123569A3 (en) Immunonanotherapeutics providing a th1-biased response
MX344329B (en) Method of treating atrial fibrillation.
WO2013166177A3 (en) Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010081091A3 (en) Therapeutic compositions for treatment of corneal disorders
WO2010028173A3 (en) Method of treating atrial fibrillation
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
EP2558102A4 (en) Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2018226894A8 (en) TREATMENT OF SKIN DISORDERS
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2007012947A3 (en) Method of treating ischemia-reperfusion injury
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2019004788A3 (en) Pharmaceutical composition containing broussochalcone a as active ingredient for prevention or treatment of inflammatory bowel disease
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09800598

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09800598

Country of ref document: EP

Kind code of ref document: A2